Denali Therapeutics Inc. (DNLI)
Largest Insider Buys in Sector
DNLI Stock Price History Chart
DNLI Stock Performance
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of …
Insider Activity of Denali Therapeutics Inc.
Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $10.14M worth of Denali Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $88.78M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.
List of Insider Buy and Sell Transactions, Denali Therapeutics Inc.
| 2024-11-11 | Sale | director | 59,441 0.0421% | $32.51 | $1.93M | -20.68% | ||
| 2024-11-07 | Sale | COFO and Secretary | 15,558 0.0109% | $29.91 | $465,286 | +0.10% | ||
| 2024-11-07 | Sale | director | 1,020 0.0007% | $30.00 | $30,600 | +0.10% | ||
| 2024-11-01 | Sale | director | 3,080 0.0022% | $27.07 | $83,376 | +9.33% | ||
| 2024-10-18 | Sale | President and CEO | 40,000 0.028% | $27.69 | $1.11M | -1.38% | ||
| 2024-09-30 | Sale | director | 30,000 0.0208% | $29.03 | $870,900 | -5.87% | ||
| 2024-09-13 | Sale | director | 1,020 0.0007% | $30.00 | $30,600 | -9.00% | ||
| 2024-09-03 | Sale | director | 3,080 0.0021% | $25.00 | $77,007 | +9.97% | ||
| 2024-08-21 | Sale | COFO and Secretary | 2,547 0.0018% | $24.78 | $63,115 | +8.52% | ||
| 2024-08-21 | Sale | Chief Medical Officer | 20,005 0.0137% | $24.57 | $491,571 | +8.52% | ||
| 2024-08-20 | Sale | President and CEO | 2,260 0.0016% | $23.79 | $53,765 | +14.38% | ||
| 2024-08-20 | Sale | COFO and Secretary | 5,806 0.0041% | $23.65 | $137,286 | +14.38% | ||
| 2024-08-20 | Sale | Chief Medical Officer | 2,453 0.0017% | $23.79 | $58,357 | +14.38% | ||
| 2024-08-20 | Sale | director | 1,727 0.0012% | $23.79 | $41,085 | +14.38% | ||
| 2024-08-13 | Sale | COFO and Secretary | 2,272 0.0016% | $22.89 | $52,006 | 0.00% | ||
| 2024-08-13 | Sale | Chief Medical Officer | 2,337 0.0017% | $22.89 | $53,494 | 0.00% | ||
| 2024-07-01 | Sale | director | 3,080 0.0022% | $22.14 | $68,204 | 0.00% | ||
| 2024-07-01 | Sale | director | 30,000 0.0212% | $22.12 | $663,668 | 0.00% | ||
| 2024-06-13 | Sale | director | 688 0.0005% | $21.79 | $14,992 | +14.15% | ||
| 2024-06-06 | Sale | director | 1,458 0.001% | $21.73 | $31,682 | +17.97% |
Insider Historical Profitability
| BRATTON DOUGLAS K | 10 percent owner | 9984836 6.9377% | $24.28 | 1 | 12 | <0.0001% |
Institutional Investor Ownership
| Baillie Gifford Co | $288.13M | 9.85 | 14.04M | -1.54% | -$4.5M | 0.22 | |
| BlackRock | $250.34M | 8.56 | 12.2M | +5.69% | +$13.47M | 0.01 | |
| The Vanguard Group | $225.07M | 7.69 | 10.97M | +1.24% | +$2.75M | <0.01 | |
| Wellington Management Company | $169.7M | 5.8 | 8.27M | +13.68% | +$20.42M | 0.03 | |
| State Street | $129.77M | 4.43 | 6.32M | +15.27% | +$17.19M | 0.01 |